TABLE 4.
Baseline characteristics of pre-vaccination versus vaccinated VTE and ATE patients.
| Characteristic | Hospital CDM (United States) | IMASIS (ES) | CPRD (United Kingdom) | SIDIAP (ES) | IPCI (NL) | LPD France (FR) | DA Germany (DE) | Open Claims (United States) | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Pre-vaccination cohort | VTE | Number of patients | 445,546 | 1,455 | 131,184 | 32,925 | 24,071 | 43,036 | 96,939 | 8,133,455 |
| Treated, % | 28.1 | 64.4 | 12.5 | 53.1 | 22.0 | 27.8 | 22.9 | 20.8 | ||
| Follow up time after index (days), Mean | 469.9 | 529.7 | 706 | 688.7 | 792.2 | 739.9 | 747.9 | 868.7 | ||
| Gender: Male, % | 48.0 | 50.2 | 50.0 | 49.4 | 45.2 | 47.7 | 45.5 | 47.9 | ||
| Age at index (years), Mean (SD) | 62.4 (12.1) | 68.7 (14.2) | 64.2 (13.3) | 68.6 (13.9) | 62.5 (11.9) | 70.7 (12.4) | 67.8 (13.0) | 64.2 (12.5) | ||
| Charlson comorbidity index, Mean (SD) | 3.8 (3.3) | 2.5 (2.7) | 1.9 (2.0) | 3.3 (2.9) | 1.5 (1.7) | 1.0 (1.3) | 2.8 (2.8) | 4.2 (3.5) | ||
| ATE | Number of patients | 859,044 | 4,364 | 195,692 | 95,081 | 117,798 | 221,716 | 193,918 | 25,780,080 | |
| Treated, % | 28.5 | 60.6 | 4.7 | 41.1 | 6.8 | 22.0 | 9.4 | 6.9 | ||
| Follow up time after index (days), Mean | 420.8 | 550.9 | 765.1 | 715.9 | 775.6 | 769.8 | 792.3 | 775.4 | ||
| Gender: Male, % | 54.7 | 58.1 | 67.4 | 58.6 | 66.2 | 73.6 | 62.2 | 51.1 | ||
| Age at index (years), Mean (SD) | 66.4 (14.5) | 72.2 (16.4) | 68.0 (16.9) | 73.1 (16.2) | 69.2 (16.0) | 68.8 (14.2) | 70.1 (15.5) | 69.3 (15.0) | ||
| Charlson comorbidity index, Mean (SD) | 4.7 (3.5) | 2.6 (3.2) | 2.7 (2.) | 3.9 (3.2) | 2.5 (1.5) | 1.8 (1.4) | 3.8 (2.9) | 5.7 (3.5) | ||
| Vaccinated cohort | VTE | Number of patients | 784 | 10 | 3,800 | 1,051 | 346 | 140 | 724 | 81,150 |
| Treated, % | 16.8 | 70.0 | 9.5 | 45.2 | 25.1 | 60 | 28.6 | 23.4 | ||
| Follow up time after index (days), Mean | 71.3 | 56.2 | 58.3 | 56.3 | 44.3 | 128.1 | 113 | 175.3 | ||
| Gender: Male, % | 49.6 | 50.0 | 49.2 | 46.9 | 46 | 62.1 | 49.7 | 48.3 | ||
| Age at index (years), Mean (SD) | 66.8 (14.4) | 60.8 (10.4) | 68.1 (15.6) | 73.3 (13.8) | 66.9 (11.2) | 72.9 (10.5) | 68.3 (13.2) | 65.5 (14.4) | ||
| Charlson comorbidity index, Mean (SD) | 4.1 (3.6) | 3.4 (2.8) | 2.1 (2.2) | 3.4 (3.1) | 1.6 (1.6) | 1.4 (1.2) | 3.5 (3.1) | 4.7 (3.6) | ||
| ATE | Number of patients | 1,334 | 21 | 3,841 | 2,820 | 1,408 | 639 | 1,446 | 197,811 | |
| Treated, % | 17.5 | 47.6 | 3.7 | 32.8 | 9.4 | 55.9 | 10.8 | 7.6 | ||
| Follow up time after index (days), Mean | 68.5 | 68 | 58.3 | 54 | 44.3 | 139.1 | 123.3 | 174.9 | ||
| Gender: Male, % | 55.0 | 66.7 | 65.7 | 59.3 | 67.5 | 76.1 | 67.4 | 51.8 | ||
| Age at index (years), Mean (SD) | 68.1 (11.0) | 66.7 (10.3) | 70.2 (12.8) | 75.2 (12.4) | 69.7 (10.1) | 67.8 (10.2) | 68.1 (11.4) | 69.3 (12.4) | ||
| Charlson comorbidity index, Mean (SD) | 4.7 (3.3) | 5.5 (4.0) | 2.7 (2.1) | 3.9 (2.9) | 2.6 (1.7) | 2.1 (1.6) | 4.0 (2.8) | 6.2 (3.6) |